SEC Form 4 · accession 0000911916-17-000083

CoLucid Pharmaceuticals, Inc. · CLCD

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Director

Period of report

Mar 1, 2017

Accepted (ET)

Mar 1, 2017 · 12:30 pm EST

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001348649

Table I — non-derivative securities

No Table I lines on this filing.

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	D/I
Stock Option (Right to Buy)^F1	$8.60	Mar 1, 2017	D	6,577	D	—	Jul 9, 2025	Common Stock	6,577	D
Stock Option (Right to Buy)^F1	$8.50	Mar 1, 2017	D	997	D	—	Jan 4, 2026	Common Stock	997	D
Stock Option (Right to Buy)^F2	$6.24	Mar 1, 2017	D	8,897	D	—	May 10, 2026	Common Stock	8,897	D
Stock Option (Right to Buy)^F1	$9.62	Mar 1, 2017	D	1,630	D	—	Jul 1, 2026	Common Stock	1,630	D
Stock Option (Right to Buy)^F1	$36.20	Mar 1, 2017	D	453	D	—	Jan 3, 2027	Common Stock	453	D

F1Pursuant to the terms of the Agreement and Plan of Merger, dated January 17, 2017 (the "Merger Agreement"), by and among CoLucid Pharmaceuticals, Inc. (the "Issuer"), Eli Lilly and Company ("Lilly") and ProCar Acquisition Corporation, a wholly-owned subsidiary of Lilly, these options, which were fully vested, were cancelled in exchange for a cash payment of $46.50 less the per share exercise price multiplied by the number of unexercised options, without interest.
F2Pursuant to the terms of the Merger Agreement, these options, which provided for full vesting immediately prior to the start of the Issuer's first annual meeting of stockholders following the date of grant, were cancelled in exchange for a cash payment of $46.50 less the per share exercise price multiplied by the number of unexercised options, without interest.